NYSE - Nasdaq Real Time Price • USD
Pfizer Inc. (PFE)
At close: April 26 at 4:01 PM EDT
After hours: April 26 at 7:59 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 16 | 16 | 23 | 22 |
Avg. Estimate | 0.49 | 0.41 | 2.06 | 2.54 |
Low Estimate | 0.34 | 0.33 | 1.91 | 2.11 |
High Estimate | 0.76 | 0.52 | 2.2 | 2.99 |
Year Ago EPS | 1.23 | 0.67 | 1.84 | 2.06 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 14 | 13 | 23 | 22 |
Avg. Estimate | 13.06B | 12.26B | 55.94B | 58.45B |
Low Estimate | 11.88B | 11.8B | 54.52B | 54.3B |
High Estimate | 15.34B | 13.04B | 56.75B | 61.05B |
Year Ago Sales | 16.59B | 12.73B | 58.5B | 55.94B |
Sales Growth (year/est) | -21.30% | -3.80% | -4.40% | 4.50% |
Earnings History
CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
---|---|---|---|---|
EPS Est. | 0.98 | 0.57 | -0.34 | -0.22 |
EPS Actual | 1.23 | 0.67 | -0.17 | 0.1 |
Difference | 0.25 | 0.1 | 0.17 | 0.32 |
Surprise % | 25.50% | 17.50% | 50.00% | 145.50% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | 0.49 | 0.41 | 2.06 | 2.54 |
7 Days Ago | 0.5 | 0.42 | 2.07 | 2.56 |
30 Days Ago | 0.5 | 0.42 | 2.03 | 2.55 |
60 Days Ago | 0.52 | 0.45 | 2.2 | 2.74 |
90 Days Ago | 0.55 | 0.44 | 2.09 | 2.5 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | 1 | -- | 2 | 2 |
Up Last 30 Days | 5 | 1 | 9 | 7 |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | 2 | 1 | 1 | -- |
Growth Estimates
CURRENCY IN USD | PFE | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | -60.20% | -- | -- | 6.50% |
Next Qtr. | -38.80% | -- | -- | 12.00% |
Current Year | 12.00% | -- | -- | 5.30% |
Next Year | 23.30% | -- | -- | 13.10% |
Next 5 Years (per annum) | -1.24% | -- | -- | 11.09% |
Past 5 Years (per annum) | 0.52% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/18/2024 |
Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/15/2024 |
Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/5/2024 |
Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/1/2024 |
Downgrade | Argus Research: Buy to Hold | 3/22/2024 |
Reiterates | Cantor Fitzgerald: Overweight to Overweight | 3/4/2024 |
Related Tickers
BMY Bristol-Myers Squibb Company
44.85
+0.34%
JNJ Johnson & Johnson
146.14
-0.46%
ABBV AbbVie Inc.
159.62
-4.58%
MRK Merck & Co., Inc.
131.20
+0.37%
GILD Gilead Sciences, Inc.
65.42
+0.23%
LLY Eli Lilly and Company
733.51
+1.19%
AZN AstraZeneca PLC
75.17
+0.19%
BIIB Biogen Inc.
208.90
+3.18%
AMGN Amgen Inc.
269.98
+0.22%
GSK GSK plc
41.11
+0.49%